Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial

INTRODUCTION: The randomized, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and skin clearance (Psoriasis Area and...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, Kristian, Kristensen, Lars Erik, Smith, Saxon D., Rich, Phoebe, Sapin, Christophe, Leage, Soyi Liu, McKenzie, Robert, Schuster, Christopher, Riedl, Elisabeth, Gooderham, Melinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116563/
https://www.ncbi.nlm.nih.gov/pubmed/35646453
http://dx.doi.org/10.5826/dpc.1202a104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116563/
https://www.ncbi.nlm.nih.gov/pubmed/35646453
http://dx.doi.org/10.5826/dpc.1202a104

Ejemplares similares